Copyright © 2002 by the European Society of Cardiology.
Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial
a Research Center, Montreal, Quebec, Canada
b Department of Medicine, Montreal, Quebec, Canada
c Biostatistics Department, Montreal, Quebec, Canada
d Department of Psychosomatic Medicine, Montreal, Quebec, Canada
revised September 5, 2001; accepted September 6, 2001
Abstract
Background Atrial fibrillation is the most common sustained cardiac arrhythmia, and engenders significant health care costs. The impact of various treatment options for atrial fibrillation on hospital costs has not been evaluated in a randomized trial.
Methods We analysed 1-year follow-up data on 392 patients randomized to low dose amiodarone (200mg.day–1) or alternative first-line therapy (sotalol or propafenone) in a multicentre trial (Canadian Trial of Atrial Fibrillation, CTAF).
Results Patients in the amiodarone group had fewer electrical cardioversions (65 vs 109 for patients in the sotalol/propafenone group,P <0·0001), and pacemaker insertions (4 vs 11, P=0·07). The average amiodarone patient spent fewer days in hospital (0·47 vs 0·97, P=0·01), and incurred lower costs ($532 vs $898,P =0·03), for admissions where atrial fibrillation was the admitting diagnosis. Average total hospital costs per patient for all admissions, as well as average combined hospital and physician costs per patient, showed wide variations within the treatment arms and were not significantly different between groups.
Conclusion For patients in whom antiarrhythmic drug therapy is indicated, low dose amiodarone significantly reduces atrial fibrillation-related costs by reducing the number of atrial fibrillation-related procedures. Copyright 2001 The European Society of Cardiology. Published by Elsevier Science Ltd. All rights reserved.
Key Words: Antiarrhythmic drugs, amiodarone, cost analysis, health economics, electrocardiogram, atrial fibrillation
f1 Correspondence: S. Nattel, MD, Research Center, Montreal Heart Institute, 5000 Belanger Street East, Montreal, Quebec, HlT 1C8, Canada.
References
- Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution and gender of patients with AF. Arch Intern Med. 1995;155:469–473
[Abstract/Free Full Text] - Dell'Orfano JT, Patel H, Wolbrette DL, Luck JC, Naccarelli GV. Acute treatment of AF: spontaneous conversion and cost of care. Am J Cardiol. 1999;83:788–790[CrossRef][Web of Science][Medline]
- Wolf, PA, Mitchell, JB, Baker, CS, Kannel, WB, D'Agostino, RB, Impact of AF on mortality, stroke and medical costs, Arch Intern Med, 1998, 158, 229, 34, Arch Intern Med, 1998, 158, 2265, 6
- Catherwood E, Fitzpatrick WD, Greenberg ML. Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular AF. Ann Intern Med. 1999;130:625–636
[Abstract/Free Full Text] - Eckman MH, Falk RH, Pauker SG. Cost-effectiveness of therapies for patients with nonvalvular AF. Arch Intern Med. 1998;158:1669–1677
[Abstract/Free Full Text] - Waldo AL, Prystowsky EN. Drug treatment of AF in the managed care era. Am J Cardiol. 1998;81:23C–29C[CrossRef][Web of Science][Medline]
- Roy D, Talajic M, Dorian P. Amiodarone to Prevent Recurrence of AF. N Engl J Med. 2000;342:913–920
[Abstract/Free Full Text] - Roy D, Talajic M, Thibault B. Pilot Study and protocol of the Canadian Trial of AF (CTAF). Am J Cardiol. 1997;80:464–468[CrossRef][Web of Science][Medline]
- Pollak PT. Clinical organ toxicity of antiarrhythmic compounds: ocular and pulmonary manifestations. Am J Cardiol. 1999;84:37R–45R[Web of Science][Medline]
- Guide to Case Costing Version 2.0, www.occp.com
- Julian DG, Camm AJ, Frangin G. Randomized trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet. 1997;349:667–674[CrossRef][Web of Science][Medline]
- Cairns JA, Connolly SJ, Roberts R, Gent M. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAIMT. Lancet. 1997;349:675–682[CrossRef][Web of Science][Medline]
- Vorperian KR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol. 1997;30:791–798[Abstract]
- Singh SN, Fisher SG, Deedwania PC, Rohatgi P, Singh BN, Fletcher RD. Pulmonary effect of amiodarone in patients with heart failure. The Congestive Heart Failure-Survival Trial of Antiarrhythmic Therapy (CHF-STAT). J Am Coll Cardiol. 1997;30:514–517[Abstract]
- Red book: pharmacy's fundamental reference. Montvale: Medical Economics Data; 2000.
- McGinley L, Cloud DS. U.S. to Reduce Payments for Medicare-Covered Drugs. The Wall Street Journal. 2000;:B6
- Rouleau JL, Moye LA, Pfeffer MA. A comparison of management patterns after acute myocardial infarction in Canada and the United States. N Engl J Med. 1993;328:779–784
[Abstract/Free Full Text] - Redelmeier DA, Fuchs VR. Hospital expenditures in the United States and Canada. N Engl J Med. 1993;328:772–778
[Abstract/Free Full Text] - Welch WP, Verrilli D, Katz SJ, Latimer E. A detailed comparison of physician services for the elderly in the United States and Canada. JAMA. 1996;275:1410–1416
[Abstract/Free Full Text] - Tu JV, Pashos CL, Naylor CD. Use of cardiac procedures and outcomes in elderly patients with myocardial infarction in the United States and Canada. N Engl J Med. 1997;336:1500–1505
[Abstract/Free Full Text] - Pilote L, Califf RM, Sapp S. Regional variation across the United States in the management of acute myocardial infarction. N Engl J Med. 1995;333:565–572
[Abstract/Free Full Text]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. R. Zebis, T. D. Christensen, I. S. Kristiansen, and V. E. Hjortdal Amiodarone Cost Effectiveness in Preventing Atrial Fibrillation After Coronary Artery Bypass Graft Surgery Ann. Thorac. Surg., January 1, 2008; 85(1): 28 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Da Costa, J. Thevenin, F. Roche, C. Romeyer-Bouchard, L. Abdellaoui, M. Messier, L. Denis, E. Faure, R. Gonthier, G. Kruszynski, et al. Results From the Loire-Ardeche-Drome-Isere-Puy-de-Dome (LADIP) Trial on Atrial Flutter, a Multicentric Prospective Randomized Study Comparing Amiodarone and Radiofrequency Ablation After the First Episode of Symptomatic Atrial Flutter Circulation, October 17, 2006; 114(16): 1676 - 1681. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C L Hu, H Jiang, Q Z Tang, Q H Zhang, J B Chen, C X Huang, and G S Li Comparison of rate control and rhythm control in patients with atrial fibrillation after percutaneous mitral balloon valvotomy: a randomised controlled study Heart, August 1, 2006; 92(8): 1096 - 1101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Zohar, M. Kovacic, M. Brezocnik, and M. Podbregar Prediction of maintenance of sinus rhythm after electrical cardioversion of atrial fibrillation by non-deterministic modelling Europace, January 1, 2005; 7(5): 500 - 507. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. E. Hagens, K. M. Vermeulen, E. M. TenVergert, D. J. Van Veldhuisen, H. A. Bosker, O. Kamp, J. H. Kingma, J. G.P. Tijssen, H. J.G.M. Crijns, I. C. Van Gelder, et al. Rate control is more cost-effective than rhythm control for patients with persistent atrial fibrillation -- results from the RAte Control versus Electrical cardioversion (RACE) study Eur. Heart J., September 1, 2004; 25(17): 1542 - 1549. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Galperin, M. V. Elizari, P. A. Chiale, R. T. Molina, R. Ledesma, A. O. Scapin, M. V. Blanco, R. Bonato, M. Lago, and Grupo de Estudio de Fibrilacion Auricular Con Amio Pharmacologic Reversion of Persistent Atrial Fibrillation with Amiodarone Predicts Long-Term Sinus Rhythm Maintenance Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2003; 8(3): 179 - 186. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Nattel Rhythm versus rate control for atrial fibrillation management: what recent randomized clinical trials allow us to affirm Can. Med. Assoc. J., March 4, 2003; 168(5): 572 - 573. [Full Text] [PDF]
|
|
|
|
|
|
A. Krahn, G. Klein, A.C. Skanes, and R. Yee Amiodarone: pearl or peril? Eur. Heart J., July 1, 2002; 23(13): 1001 - 1002. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||